NASDAQ : RLYB
Rallybio Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 15.41 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 81.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 83.67M |
| Enterprise Value | -7.03M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 5.38M |
| Shares Outstanding | 5.38M |
| Shares Change (YoY) | +2.81% |
| Shares Change (QoQ) | -1.43% |
| Owned by Insiders (%) | 20.66% |
| Owned by Institutions (%) | 37.97% |
| Float | 1.73M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 3.34 |
| Forward PE | n/a |
| PS Ratio | 192.78 |
| Forward PS | n/a |
| PB Ratio | 0.90 |
| P/TBV Ratio | 0.91 |
| P/FCF Ratio | 2.70 |
| P/OCF Ratio | 2.70 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 28.87 |
| Quick Ratio | 27.63 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 34.52% |
| Return on Assets (ROA) | -16.79% |
| Return on Invested Capital (ROIC) | -17.62% |
| Return on Capital Employed (ROCE) | -23.75% |
| Weighted Average Cost of Capital (WACC) | 0.32% |
| Revenue Per Employee | $62,000 |
| Profits Per Employee | $3.83M |
| Employee Count | 7 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.40M |
| Effective Tax Rate | 4.98% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.71 |
| 52-Week Price Change | +220.94% |
| 50-Day Moving Average | 16.73 |
| 200-Day Moving Average | 12.93 |
| Relative Strength Index (RSI) | 33.81 |
| Average Volume (20 Days) | 20,837 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 40,962 |
| Short Previous Month | 49,245 |
| Short % of Shares Out | 0.76% |
| Short % of Float | 2.37% |
| Short Ratio (days to cover) | 4.76 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 434,000 |
| Gross Profit | -5.83M |
| Operating Income | -21.92M |
| Pretax Income | 28.21M |
| Net Income | 26.81M |
| EBITDA | -21.91M |
| EBIT | -21.92M |
| Earnings Per Share (EPS) | $4.65 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 90.69M |
| Total Debt | n/a |
| Net Cash | 90.69M |
| Net Cash Per Share | $16.85 |
| Equity (Book Value) | 92.30M |
| Book Value Per Share | 17.31 |
| Working Capital | 91.49M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 30.99M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 8,000 |
| Net Borrowing | n/a |
| Free Cash Flow | 30.99M |
| FCF Per Share | $5.76 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -5,050.92% |
| Pretax Margin | 6,500.92% |
| Profit Margin | 6,177.42% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | 7,139.63% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.81% |
| Shareholder Yield | -2.81% |
| Earnings Yield | 29.94% |
| FCF Yield | 37.04% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 6, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 6.48 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |